MYC acts as a negative regulator of lncRNA to inhibit transcription of FGF13-AS1, forming an FGF13-AS1/IGF2BPs/MYC feedback pathway to inhibit breast cancer development and glycolysis [57]. Here, MYC is linked to breast carcinoma.